Desmopressin Stimulates Parallel Norepinephrine and Tissue Plasminogen Activator Release in Normal Subjects and Patients with Diabetes Mellitus

Summary

Desmopressin acetate administration markedly stimulates release of tissue plasminogen activator (t-PA) from vascular endothelial cells. The mechanism for this effect is unknown. Because infusion of epinephrine has been shown to increase t-PA levels, we examined the role of endogenous catecholamine mediation of t-PA release by desmopressin. Intravenous desmopressin acetate (0.3 μg/kg) was infused over 30 min in 9 controls and 11 subjects with diabetes mellitus, a condition associated with abnormalities of the fibrinolytic system. Plasma was collected in the supine, overnight fasted state at 15 min intervals (0-60 min) for measurement of t-PA activity, t-PA antigen and fractionated catecholamines. t-PA activity peaked at 30-45 min and subsequently decreased. The norepinephrine levels paralleled the t-PA activity. t-PA activity increased 10-fold from 0.14 ± .12 to 1.49 ± 0.79 IU/ml (Mean ± SD) and plasma norepinephrine increased 2- fold from 426 ± 90 to 780 ± 292 pg/ml. However, epinephrine and dopamine levels did not change significantly. The response to desmopressin of control and diabetic subjects was not shown to differ and their data were combined. We conclude that desmopressin increases plasma norepinephrine in addition to t-PA and that the parallel time course of change suggests a possible role for norepinephrine in mediating endothelial cell t-PA release.

Keywords

Desmopressin - Norepinephrine - Tissue plasminogen activator release (t-PA) - Catecholamines - Endothelial cells

• References

• 1 Innes D, Sevitt S. Coagulation and fibrinolysis in injured patients. J Clin Pathol 1964; 17: 1-13
• 2 Lands AM, Arnold A, McAuliff JP, Ludrena FP, Brown TG. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597-598
• 3 MacFarlane RG, Biggs R. Observations on fibrinolysis: Spontaneous activity associated with surgical operations, trauma, etc. Lancet 1946; 2: 862-864
• 4 Cash JD. Neurohumoral pathways associated with the release of plasminogen activator in man. In: Progress in Chemical Fibrinolysis and Thrombolysis Vol. 1. Davidson JF, Samama MM, Desnoyers PC. (eds.) Raven Press; New York: 1975. p 97-107
• 5 Gader AM A, Clarkson AR, Cash JD. The plasminogen activator and coagulation factor VIII responses to adrenaline, noradrenaline, isoprenalene and salbutamol in man. Thromb Res 1973; 2: 9-16
• 6 Gader AM A, DaCosta J, Cash JD. The effect of propranolol, alprenolol and practolol on the fibrinolytic and factor VIII responses to adrenaline and salbutamol in man. Thromb Res 1974; 4: 25-33
• 7 Conanan LB, Crutchley DJ. Serum-dependent induction of plasminogen activator in human fibroblasts by catecholamines and comparison with the effects of prostaglandin El. Biochim Biophys Acta 1983; 759: 146-153
• 8 Kjaeldgaard A, Kjaeldgaard M. In vitro stimulation of plasminogen activator release from vein walls by adrenaline. J Clin Pathol 1986; 39 (11) 1241-1244
• 9 Moffat EH, Giddings JC, Bloom AL. The effect of desamino-D- arginine vasopressin (DDAVP) and naloxone infusions on Factor VIII and possible endothelial cell (EC) related activities. Br J Haematol 1984; 57: 651-662
• 10 Mannucci PM, Canciani MT, Roto L, Donovan BS. Response of factor VUI/von Willebrand’s factor to DDAVP in healthy subjects and patients with haemophilia and von Willebrand’s disease. Br J Haematol 1979; 43: 283-293
• 11 Mannucci PM, Remucci G, Pasineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS. Deamino-8-d-arginine vasopressin shortens the bleeding time in.uremia. N Engl J Med 1983; 308: 8-12
• 12 Christe M, Fritschi J, Lammle B, Tran TH, Marbet GA, Berger W, Duckert F. Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 1984; 52: 138-143
• 13 Aimer LO, Nilsson IM. On fibrinolysis in diabetes mellitus. Acta Med Scand. 1975; 198: 101-106
• 14 Knaap JH, DeBoer AC, Pannebakker MA G, von Heerde W, den Ottolander GJ H. The effect of diabetes regulation on platelet release, fibrinolysis and coagulation tests, before and after stimulation with DDAVP. Thromb Haemostas 1985; 53: 118-121
• 15 Leveston SA, Shah SD, Cryer PE. Cholinergic stimulation of norepinephrine release in man: Evidence of a sympathetic post ganglionic axonal lesion in diabetic adrenergic neuropathy. J Clin Invest 1979; 64: 374-379
• 16 Lou PA, Walsh JC, Huang CY, McLeod JC. The sympathetic nervous system in diabetic neuropathy: A clinical and pathologic study. Brain 1975; 98: 341-356
• 17 National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other catagories of glucose intolerance. Diabetes. 1979; 28: 1039-1057
• 18 Ewing DJ, Borsey DQ, Bellavere F, Clarke BF. Cardiac autonomic neuropathy in diabetics: Comparison of measures of RR interval variation. Diabetologia 1981; 21: 18-24
• 19 Christensen NJ. Plasma catecholamines in long-term diabetics with and without neuropathy and in hypophysectomized subjects. J Clin Invest 1972; 51: 779-787
• 20 Zeigler MG, Lake RC, Kopin IJ. The sympathic nervous system defect in primary orthostatic hypotension. N Engl J Med 1977; 296: 293-297
• 21 Cryer PE. Isotope-derivative measurements of plasma norepinephrine and epinephrine in man. Diabetes 1976; 25: 1071-1082
• 22 Chmielewska JN, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1986; 32: 482-485
• 23 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
• 24 Binder SR, Nelson MA. Electroanalytical symposium. BAS Press; 1985: 24-24